Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amlodipine/chlortalidone/telmisartan - Yuhan

Next Previous
Drug Profile

Amlodipine/chlortalidone/telmisartan - Yuhan

Alternative Names: Amlodipine/telmisartan/chlortalidone; Chlortalidone/amlodipine/telmisartan; Chlortalidone/telmisartan/amlodipine; Telmisartan/amlodipine/chlortalidone; Telmisartan/chlortalidone/amlodipine; YH 22162; YH22162 FDC

Latest Information Update: 20 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yuhan
  • Class Antihypertensives; Benzimidazoles; Benzoates; Dihydropyridines; Ischaemic heart disorder therapies; Isoindoles; Small molecules; Sulfonamides
  • Mechanism of Action ACE inhibitors; Angiotensin type 2 receptor antagonists; Calcium channel antagonists; Thiazide-like diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Hypertension

Most Recent Events

  • 20 Sep 2023 Amlodipine/chlortalidone/telmisartan is still in Preregistration phase for Hypertension in South Korea
  • 08 Oct 2021 No development reported - Preregistration for Hypertension (Treatment-experienced) in South Korea (PO)
  • 20 Feb 2019 Amlodipine/chlortalidone/telmisartan is still in phase III trial for Hypertension in South Korea

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top